Effect of Left Ventricular Assist Device Infection on Post-transplant Outcomes

2009 ◽  
Vol 28 (3) ◽  
pp. 237-242 ◽  
Author(s):  
Allison R. Schulman ◽  
Timothy P. Martens ◽  
Mark J. Russo ◽  
Paul J. Christos ◽  
Rachel J. Gordon ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Post Transplant ◽  
Transplant Outcomes ◽  
Device Infection ◽  
Left Ventricular Assist

Left Ventricular Assist Device Infection Is Associated With Increased Mortality but Is Not a Contraindication to Transplantation

Circulation ◽  
1997 ◽  
Vol 95 (4) ◽  
pp. 814-817 ◽  
Author(s):  
Mathias Herrmann ◽  
Michael Weyand ◽  
Britta Greshake ◽  
Christof von Eiff ◽  
Richard A. Proctor ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Device Infection ◽  
Left Ventricular Assist

scholarly journals Two-Case Series of Heart Transplant at a Single Center in a SARS-CoV-2 Epicenter

2021 ◽  
Author(s):  
Marlena Sabatino ◽  
Cassandra Soto ◽  
Krish Dewan ◽  
Joshua Chao ◽  
Hirohisa Ikegami ◽  
...  
Keyword(s):  
Ejection Fraction ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Academic Medical Center ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Post Transplant ◽  
Definitive Therapy ◽  
Left Ventricular Assist

As SARS-CoV-2 continues to challenge hospital systems, the safety of heart transplantation must be evaluated. Retrospective review of all heart recipients transplanted at a single academic medical center in a U.S. SARS-CoV-2 epicenter found two patients with non-ischemic dilated cardiomyopathy. The 34-year-old male (ejection fraction <10%) was bridged to transplant with extracorporeal membrane oxygenation and microaxial left ventricular assist device. His perioperative course was uncomplicated except for transient SARS-CoV-2 seropositivity two months post-transplant. He was asymptomatic and remained so eight months to follow. The 20-year-old female (ejection fraction 5%) was bridged to transplant with microaxial left ventricular assist device. She progresses well with SARS-CoV-2 seronegativity eight months post-transplant. Our early experience suggests that intentional recipient, donor, and provider testing, cautious organ procurement, strategic intrahospital patient organization and transport, and well-coordinated follow-up permits uninterrupted provision of this definitive therapy for heart failure without subjecting these patients to greater risk.

Sign in / Sign up

Export Citation Format

Share Document